Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06116890 · ClinicalTrials.gov registry record · Phase 2

Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration

A Phase 2 study of Neovascular Age-related Macular Degeneration (nAMD), sponsored by Kyowa Kirin Co..

Active
Registry status
Phase 2
Development phase
180
Enrollment target
20
Study locations

NCT06116890: Active Phase 2 study of Neovascular Age-related Macular Degeneration (nAMD), sponsored by Kyowa Kirin Co..

NCT06116890 is a Phase 2 study of Neovascular Age-related Macular Degeneration (nAMD) that is active but no longer recruiting, run by Kyowa Kirin Co.. The registered enrollment target is 180 participants, roughly in line with the 188-participant average among 9 other Neovascular Age-related Macular Degeneration (nAMD) trials with a reported enrollment target. The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06116890, a Phase 2 study of Neovascular Age-related Macular Degeneration (nAMD), is active but no longer recruiting, sponsored by Kyowa Kirin Co..

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
180 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to evaluate efficacy and safety of KHK4951 eye drops in patients with nAMD.

Conditions Studied

Neovascular Age-related Macular Degeneration (nAMD)

Interventions

  • DRUG Aflibercept Injection
  • DRUG KHK4951

Study Locations (20)

Florida

  • Blue Ocean Clinical Research West - Clearwater
  • Florida Eye Associates - Melbourne
  • Eye Associates of Pinellas - Pinellas Park
  • Ft. Lauderdale Eye Institute - Plantation
  • Retina Vitreous Associates of Florida - Saint Petersburg - St. Petersburg
  • Southern Vitreoretinal Associates - Tallahassee
  • Center for Retina and Macular Disease - Ophthalmology - Winter Haven

California

  • Win Retina - Arcadia
  • Retina Vitreous Associates Medical Group - Beverly Hills
  • The Retina Partners - Encino
  • Salehi Retina Institute, Inc - Huntington Beach
  • Payam Amini - Pasadena

Arizona

  • Barnet Dulaney Perkins Eye Center - Phoenix - Mesa
  • Retina Associates Southwest, P.C. - Tucson

Colorado

  • Retina Consultants of Southern CO - Colorado Springs

Georgia

  • Southeast Retina Center - Augusta

Massachusetts

  • Massachusetts Eye and Ear - Boston

Michigan

  • Associated Retinal Consultants (ARC) P.C. - Opthalmology - Royal Oak

Nevada

  • Sierra Eye Associates - Reno

Trial Details

FieldValue
Enrollment Target 180 participants
Start Date 2024-01-31
Est. Completion 2026-09-30
Phase Phase 2
Kyowa Kirin Co.

25 total trials

What the registry record for NCT06116890 still lists

NCT06116890 is an interventional study that assigns participants to a tested intervention. The registered 180 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 188-participant average among 9 other Neovascular Age-related Macular Degeneration (nAMD) trials with a reported enrollment target.

The record links to 1 condition, with Neovascular Age-related Macular Degeneration (nAMD) appearing as the primary indexed condition, and to 2 interventions - of which Aflibercept Injection is the first listed.

NCT06116890 names 20 study sites across 9 states, led by Florida, California, Arizona.

Frequently Asked Questions

What is clinical trial NCT06116890 about?

NCT06116890 is a clinical study titled "Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration". The purpose of this study is to evaluate efficacy and safety of KHK4951 eye drops in patients with nAMD.

What is the current status of trial NCT06116890?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 180 participants. The study started on 2024-01-31. Estimated completion is 2026-09-30.

What conditions does trial NCT06116890 study?

This clinical trial studies the following conditions: Neovascular Age-related Macular Degeneration (nAMD).

What interventions are being tested in trial NCT06116890?

The interventions under investigation include: Aflibercept Injection (DRUG), KHK4951 (DRUG).

Who is sponsoring clinical trial NCT06116890?

This trial is sponsored by Kyowa Kirin Co., which has 25 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06116890 being conducted?

This trial has 20 study locations across Arizona, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Neovascular Age-related Macular Degeneration (nAMD)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06116890's enrollment target sits among peer trials

180 5th of 9 higher than 5 of 9 other Neovascular Age-related Macular Degeneration (nAMD) trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Neovascular Age-related Macular Degeneration (nAMD) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01558804 · 180 participants

    GRoup A StrePtococcus

  • NCT02932176 · 180 participants

    Machine Learning for Handheld Vascular Studies

  • NCT03384563 · 180 participants · Phase 4

    Effect of Dexmedetomidine on the Minimum Alveolar Concentration of Sevoflurane

  • NCT03423628 · 180 participants · Phase 1

    A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT06116890, the US trial registry maintained by the National Library of Medicine. NCT06116890 (mid enrollment · wide site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.